Publications by authors named "F Mornex"

Claim this Profile
W
What are the outcomes for long-term survivors after esophagectomy ? - Evidence from a randomized controlled trial (FFCD9901).
William B Robb, Julie Veziant, Laetitia Dahan, Françoise Mornex, Emilie Barbier

Eur J Surg Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Toxicity of (Chemo)Radiation Therapy in HIV+ Patients with Squamous Cell Anal Cancer, a Subgroup Analysis of the National Multicenter Cohort FFCD-ANABASE.
Cecile Evin, Laurent Quéro, Karine Le Malicot, Sarah Blanchet-Deverly, Ludovic Evesque, Françoise Mornex

Int J Radiat Oncol Biol Phys· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
A R Filippi, J Bar, C Chouaid, D C Christoph, J K Field, F Mornex

ESMO Open· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Everett E Vokes, Francoise Mornex, Ahmet Sezer, Ying Cheng, Jian Fang

J Thorac Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Byoung Chul Cho, Jong Seok Lee, Yi-Long Wu, Irfan Cicin, Manuel Cobo Dols, Francoise Mornex

J Thorac Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis